• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mental and Emotional Health of Youth after 24 months of Gender-Affirming Medical Care Initiated with Pubertal Suppression.在开始青春期抑制的性别肯定医疗护理24个月后青少年的心理和情绪健康状况
medRxiv. 2025 May 16:2025.05.14.25327614. doi: 10.1101/2025.05.14.25327614.
2
Impact of Early Medical Treatment for Transgender Youth: Protocol for the Longitudinal, Observational Trans Youth Care Study.早期医疗干预对跨性别青少年的影响:纵向观察性跨性别青少年护理研究方案
JMIR Res Protoc. 2019 Jul 9;8(7):e14434. doi: 10.2196/14434.
3
Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).用于抑制性别焦虑症青少年青春期的醋酸组氨瑞林植入剂:50微克/天(Vantas)与65微克/天(SupprelinLA)的比较
Transgend Health. 2021 Feb 15;6(1):36-42. doi: 10.1089/trgh.2020.0055. eCollection 2021 Feb.
4
The peripubertal gender-dysphoric child: puberty suppression and treatment paradigms.青春期前后性别焦虑的儿童:青春期抑制及治疗模式
Pediatr Ann. 2014 Jun;43(6):e132-7. doi: 10.3928/00904481-20140522-08.
5
Psychosocial Characteristics of Transgender Youth Seeking Gender-Affirming Medical Treatment: Baseline Findings From the Trans Youth Care Study.寻求性别肯定医疗的跨性别青年的心理社会特征:跨青年关怀研究的基线结果。
J Adolesc Health. 2021 Jun;68(6):1104-1111. doi: 10.1016/j.jadohealth.2020.07.033. Epub 2020 Aug 21.
6
Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK.英国一项针对 12 至 15 岁持续性性别焦虑青少年的选择队列研究:青春期抑制的短期结果。
PLoS One. 2021 Feb 2;16(2):e0243894. doi: 10.1371/journal.pone.0243894. eCollection 2021.
7
Use of gonadotropin-releasing hormone agonists in transgender and gender diverse youth: a systematic review.促性腺激素释放激素激动剂在跨性别和性别多样化青少年中的应用:一项系统综述。
Front Endocrinol (Lausanne). 2025 May 14;16:1555186. doi: 10.3389/fendo.2025.1555186. eCollection 2025.
8
Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy.青年性别肯定激素治疗的身体不满和心理健康结果。
Pediatrics. 2020 Apr;145(4). doi: 10.1542/peds.2019-3006.
9
Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study.青春期性别认同障碍患者的青春期抑制:一项前瞻性随访研究。
J Sex Med. 2011 Aug;8(8):2276-83. doi: 10.1111/j.1743-6109.2010.01943.x. Epub 2010 Jul 14.
10
Hormone Therapy in Children and Adolescents.儿童和青少年的激素治疗。
Endocrinol Metab Clin North Am. 2019 Jun;48(2):331-339. doi: 10.1016/j.ecl.2019.01.003. Epub 2019 Mar 22.

本文引用的文献

1
Emotional Health of Transgender Youth 24 Months After Initiating Gender-Affirming Hormone Therapy.开始性别确认激素治疗24个月后的跨性别青少年的情绪健康
J Adolesc Health. 2025 Jul;77(1):41-50. doi: 10.1016/j.jadohealth.2024.11.014. Epub 2025 Jan 16.
2
Understanding Family Support for Transgender Youth: Impact of Support on Psychosocial Functioning.了解家庭对跨性别青少年的支持:支持对心理社会功能的影响。
J Adolesc Health. 2024 Aug;75(2):261-266. doi: 10.1016/j.jadohealth.2024.04.006. Epub 2024 Jun 6.
3
Disparities and Trends in Middle School Students' Suicidal Thoughts and Behaviors: Results From the Youth Risk Behavior Survey, 2015-2019.中学生自杀意念和行为的差异和趋势:2015-2019 年青少年风险行为调查结果。
J Adolesc Health. 2024 Apr;74(4):720-728. doi: 10.1016/j.jadohealth.2023.11.008. Epub 2023 Dec 21.
4
Association of Pubertal Blockade at Tanner 2/3 With Psychosocial Benefits in Transgender and Gender Diverse Youth at Hormone Readiness Assessment.在激素准备评估时,坦纳2/3期青春期阻断与跨性别和性别多样化青少年心理社会益处的关联。
J Adolesc Health. 2024 Apr;74(4):801-807. doi: 10.1016/j.jadohealth.2023.10.028. Epub 2023 Dec 13.
5
Extended Use of Histrelin Implant in Pediatric Patients.促性腺激素释放激素类似物植入剂在儿科患者中的长期使用。
Transgend Health. 2023 Jun 1;8(3):264-272. doi: 10.1089/trgh.2021.0130. eCollection 2023 Jun.
6
Psychosocial Functioning in Transgender Youth after 2 Years of Hormones. transgender 青年激素治疗 2 年后的社会心理功能。
N Engl J Med. 2023 Jan 19;388(3):240-250. doi: 10.1056/NEJMoa2206297.
7
Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.青春期开始抑制性别认同激素的跨性别者继续使用:荷兰的一项队列研究。
Lancet Child Adolesc Health. 2022 Dec;6(12):869-875. doi: 10.1016/S2352-4642(22)00254-1. Epub 2022 Oct 21.
8
Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care.跨性别和非二元性别青年接受性别肯定护理的心理健康结果。
JAMA Netw Open. 2022 Feb 1;5(2):e220978. doi: 10.1001/jamanetworkopen.2022.0978.
9
Histrelin Implants for Suppression of Puberty in Youth with Gender Dysphoria: A Comparison of 50 mcg/Day (Vantas) and 65 mcg/Day (SupprelinLA).用于抑制性别焦虑症青少年青春期的醋酸组氨瑞林植入剂:50微克/天(Vantas)与65微克/天(SupprelinLA)的比较
Transgend Health. 2021 Feb 15;6(1):36-42. doi: 10.1089/trgh.2020.0055. eCollection 2021 Feb.
10
Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK.英国一项针对 12 至 15 岁持续性性别焦虑青少年的选择队列研究:青春期抑制的短期结果。
PLoS One. 2021 Feb 2;16(2):e0243894. doi: 10.1371/journal.pone.0243894. eCollection 2021.

在开始青春期抑制的性别肯定医疗护理24个月后青少年的心理和情绪健康状况

Mental and Emotional Health of Youth after 24 months of Gender-Affirming Medical Care Initiated with Pubertal Suppression.

作者信息

Olson-Kennedy Johanna, Durazo-Arvizu Ramon, Wang Liyuan, Wong Carolyn F, Chen Diane, Ehrensaft Diane, Hidalgo Marco A, Chan Yee-Ming, Garofalo Robert, Radix Asa E, Rosenthal Stephen M

机构信息

Division of Adolescent and Young Adult Medicine, Children's Hospital, Los Angeles, California.

Department of Pediatrics, University of Southern California, Los Angeles, California.

出版信息

medRxiv. 2025 May 16:2025.05.14.25327614. doi: 10.1101/2025.05.14.25327614.

DOI:10.1101/2025.05.14.25327614
PMID:40463525
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12132111/
Abstract

BACKGROUND AND OBJECTIVES

Medical interventions for youth with gender dysphoria can include the use of gonadotropin releasing hormone analogs (GnRHas) for suppression of endogenous puberty. This analysis aimed to understand the impact of medical intervention initiated with GnRHas on psychological well-being among youth with gender dysphoria over 24 months.

METHODS

Participants were enrolled as part of the Trans Youth Care United States Study. Eligibility criteria for youth included a diagnosis of Gender Dysphoria and pubertal initiation. Youth with precocious puberty or pre-existing osteoporosis were ineligible. Youth reported on depressive symptoms, emotional health and suicidality at baseline, 6, 12, 18 and 24 months after initiation of GnRHas. Parent/caretaker completed the Child Behavior Checklist at baseline, 12 and 24 months after initiation of GnRHas. Latent Growth-Curve Models analyzed trajectories of change over the 24-month period.

RESULTS

Ninety-four youth aged 8-16 years (mean=11.2 y) were predominately Non-Hispanic White (56%), early pubertal (86%) and assigned male at birth (52%). Depression symptoms, emotional health and CBCL constructs did not change significantly over 24 months. At no time points were the means of depression, emotional health or CBCL constructs in a clinically concerning range.

CONCLUSION

Participants initiating medical interventions for gender dysphoria with GnRHas have self- and parent-reported psychological and emotional health comparable with the population of adolescents at large, which remains relatively stable over 24 months. Given that the mental health of youth with gender dysphoria who are older is often poor, it is likely that puberty blockers prevent the deterioration of mental health.

摘要

背景与目的

针对性别焦虑症青少年的医学干预措施可包括使用促性腺激素释放激素类似物(GnRHas)来抑制内源性青春期。本分析旨在了解以GnRHas开始的医学干预对性别焦虑症青少年24个月内心理健康的影响。

方法

参与者作为美国跨性别青少年护理研究的一部分被招募。青少年的纳入标准包括性别焦虑症诊断和青春期开始。性早熟或已有骨质疏松症的青少年不符合条件。青少年在开始使用GnRHas后的基线、6个月、12个月、18个月和24个月报告抑郁症状、情绪健康和自杀倾向。父母/照顾者在开始使用GnRHas后的基线、12个月和24个月完成儿童行为检查表。潜在生长曲线模型分析了24个月期间的变化轨迹。

结果

94名年龄在8至16岁(平均 = 11.2岁)的青少年主要为非西班牙裔白人(56%),青春期早期(86%),出生时被指定为男性(52%)。抑郁症状、情绪健康和儿童行为检查表各项指标在24个月内没有显著变化。在任何时间点,抑郁、情绪健康或儿童行为检查表各项指标的均值均未处于临床关注范围。

结论

开始使用GnRHas对性别焦虑症进行医学干预的参与者自我报告和父母报告的心理及情绪健康与广大青少年群体相当,且在24个月内保持相对稳定。鉴于年龄较大的性别焦虑症青少年心理健康往往较差,青春期阻滞剂可能预防了心理健康的恶化。